分類: SeaPRwire

SINGAPORE – March 09, 2026 – (SeaPRwire) – AI Labs, an AI-driven crypto trading technology company backed by Academic Labs, announced the launch of an AI-assisted platform designed to help cryptocurrency traders analyze market data and respond more efficiently to changing market conditions. As automated tools and algorithmic strategies become more common in global digital asset markets, the platform integrates visual analysis, narrative data monitoring, and automated trade execution features intended to support more structured and data-driven trading decisions. The fastest traders in today’s crypto markets may not always be humans. As digital asset markets increasingly incorporate automation, many traders now rely on algorithmic systems that can monitor markets continuously and react to signals with minimal delay. A crypto project called AI Labs (ticker: AIX) is building an AI-enabled platform that combines visual reasoning, narrative intelligence, and automated execution to help users interpret market data and respond to signals more efficiently than traditional manual analysis alone. “Markets are entering an era where the use of artificial intelligence is becoming more common in trading strategies,” said Kingston Kwek, owner of AI Labs. “Our goal is to make analytical tools that are often used by institutional trading teams more accessible to a wider group of crypto traders.” At the center of AI Labs’ platform is a visual reasoning engine that analyzes charts not simply as static images, but as evolving market structures. Using computer vision and multimodal AI techniques, the system can identify potential liquidity zones, resistance levels, and broader market patterns within short timeframes. Alongside this, AI Labs has developed a narrative intelligence layer that scans information across the crypto ecosystem. This includes movements associated with large crypto wallets, developer updates, and shifts in online sentiment—signals that traders often monitor when assessing possible market trends. Instead of only placing individual buy or sell orders, traders can define broader trading parameters using the AI system. The platform can then execute trades automatically based on predefined conditions, such as capital inflows, volatility changes, or funding-rate shifts. The objective is to help reduce emotional decision-making and allow traders to stay aligned with their strategies while automated systems monitor market activity continuously. AI Labs’ platform is currently onboarding new users, with reported monthly trading activity exceeding $1 billion across the platform. Media Contact Brand: AI Labs (Backed by Academic Labs) Contact: Media team Email: ryan@academic-labs.org Website: https://academic-labs.org

SHENZHEN, CHINA, Mar 5, 2026 – (ACN Newswire) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”) received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration (“NMPA”) on 4 March 2026. The NMPA has approved the conduct of clinical trials of CMS-D008 injection for overweight or obese individuals. About CMS-D008 CMS-D008 is a novel siRNA therapy administered by subcutaneous injection. CMS-D008 targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of Activin E protein encoded by INHBE, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. Preclinical studies suggested that CMS-D008 efficiently and sustainably suppressed INHBE expression. In the diet-induced obesity model, CMS-D008 enhanced weight loss by reducing fat mass while retaining lean mass with a good safety profile. It demonstrates potentially better prospects for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. In the future, it may be developed for the treatment of overweight/obesity, abdominal obesity, and related metabolic diseases. Fat Loss, muscle preserved: a potentially better therapeutic option for overweight/obesity Overweight or obesity is a chronic, progressive, relapsing disease characterized by excessive accumulation or abnormal distribution or function of body fat[1]. World Obesity Atlas 2025 Report projected that the global proportion of overweight and obese adults will rise to 50%, with nearly 3 billion adults impacted by high body mass index (BMI), and the population of adults who are overweight or obese in China is projected to reach 515 million by 2030[2]. Existing GLP-1RAs have been proven to be effective for the treatment of overweight and obesity. The main actions of GLP-1RAs are to suppress appetite by acting on the central nervous system and to delay gastric emptying[3]. INHBE’s novel mechanism of action differs from GLP-1RAs. INHBE is identified through genome-wide association studies. Populations with loss of function in INHBE are associated with favorable fat distribution and beneficial metabolic characteristics[4]. Targeted inhibition of INHBE might be more conducive for long-term weight management at the genetic level with precisely lower visceral fat and favorable metabolic profiles. CMS-D008 teams up with CMS-D005: highly effective weight loss plus long-term maintenance, building a more comprehensive weight-loss solution CMS-D008 will synergize with CMS-D005, a self-developed innovative drug currently in clinical development. CMS-D008 reduces fat without sacrificing muscle mass by precisely inhibiting INHBE gene expression; while CMS-D005, as a GLP-1R/GCGR dual agonist, can effectively reduce liver fat while losing weight. The synergy between these two drugs will achieve highly effective weight loss benefits and long-term maintenance of results, jointly enhancing the Group’s R&D capabilities and product competitiveness in the field of obesity/metabolic treatment. Furthermore, leveraging the Group’s mature network resources in the field of cardiovascular and metabolic diseases, the drug’s R&D and commercialization process will be accelerated, providing patients with more comprehensive and innovative treatment options. The Group is actively preparing to initiate relevant clinical trials and strives to launch the Product as soon as possible. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference: 1. Chinese Society of Endocrinology. Guideline for chronic weight management and clinical practice of anti-obesity medications(2024 version). Chinese Journal of Endocrinology and Metabolism. 2024,40(7):545-564. 2. World Obesity Federation. World Obesity Atlas 2025. London: World Obesity Federation, 2025. https://data.worldobesity.org/publications/?cat=23 3. Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024). doi: 10.1038/s41392-024-01931-z 4. Parsa Akbari, Olukayode A Sosina, Jonas Bovijn, et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. Nat Commun.2022 Aug 23;13(1):4844. doi: 10.1038/s41467-022-32398-7. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Singapore – March 05, 2026 – (SeaPRwire) – Core Concepts Physio, one of Singapore’s leading physiotherapy providers, has announced an expanded collaborative programme with podiatry service provider, Podiatry Quest, to offer enhanced, multidisciplinary assessments for patients experiencing plantar fasciitis and stubborn heel pain. Plantar fasciitis remains one of the most common and persistent causes of heel pain among adults, especially those with active lifestyles or occupations involving long hours on their feet. Often treatment seeks to address only one aspect of the condition rather than the full movement chain, which leads to recurring pain as other aspects remain unresolved. To bridge this gap, the two clinics have formalised a joint assessment pathway that evaluates plantar fasciitis from both the top-down (physiotherapy) and the bottom-up (podiatry) so as to ensure that no contributing factor is overlooked. A Smarter, More Complete Way to Diagnose Heel Pain Physiotherapy and podiatry traditionally manage different elements of plantar fasciitis. Physiotherapists focus on mobility, strength, gait and load tolerance, while podiatrists address foot posture, footwear, ground forces and orthotic support. The new integrated pathway combines both perspectives into a single, coordinated evaluation which results in: More accurate, holistic diagnoses Fully optimised treatment strategies Fewer flare-ups and recurrences Clearer, consistent guidance for patients Faster and more sustainable outcomes “Many patients struggle because plantar fasciitis isn’t caused by just one issue,” said Mr Chng Chye Tuan, Senior Principal Physiotherapist at Core Concepts Physiotherapy. “It’s a movement chain problem involving the foot, calf, ankle mobility, daily load and footwear. When physiotherapists and podiatrists work together, we address every contributing factor — not just the symptoms.” A Case Study Demonstrating Collaborative Success In a recent case, a 42-year-old recreational runner sought help after six months of persistent heel pain. Physiotherapy improved his morning pain and running tolerance, but he continued to experience flare-ups following long work shifts. A podiatry assessment revealed prolonged pronation, footwear-related loading issues and inadequate shock absorption. With customised orthoses and tailored footwear recommendations, the patient’s daily load decreased significantly — allowing physiotherapy progress to continue without setbacks. Within 10 weeks of coordinated care, he achieved pain-free mornings, comfortable workdays and full return to running. “This case reflects what we see frequently,” said Mr Yeo Boon Kiak, Principal Podiatrist at Podiatry Quest. “Physiotherapy builds tissue capacity, strength and movement control. Podiatry reduces unnecessary strain and optimises how forces enter the foot. When combined, this creates the ideal environment for long-lasting recovery.” Making Multidisciplinary Care Accessible Nationwide Through this collaboration, patients with plantar fasciitis now benefit from: Joint physiotherapy–podiatry assessments Aligned clinical decision-making Consistent communication across providers A thorough evaluation of both the cause and consequence of heel pain A fully optimised recovery pathway “Our multidisciplinary team brings together the best of both professions,” said Mr Chng Chye Tuan. “Whether someone is a runner, a frequent traveller or stands long hours at work, this collaboration ensures their care is comprehensive, precise and built around their real-life demands.” About Core Concepts Physiotherapy Core Concepts Physio is one of Singapore’s largest private physiotherapy groups, offering evidence-based musculoskeletal and sports physiotherapy across multiple clinic locations. Their multidisciplinary approach allows clients to benefit from integrated care, ensuring complete and effective recovery. Know more please contact marketing@coreconcepts.com.sg or call +65 62263632 or visit our office at 6 Raffles Quay, #11-01, Singapore 048580. About Podiatry Quest Podiatry Quest specialises in diagnosing and treating foot, ankle and lower limb conditions. Led by experienced podiatrists, the clinic offers services such as customised orthoses, biomechanical assessments, gait analysis and comprehensive podiatric care. Contact Details Organization: Core Concepts Pte Ltd Contact: Clemence Lim Email: marketing@coreconcepts.com.sg Website: https://www.coreconceptsphysio.sg

Base58 Labs Advances Integration of Proprietary BHLE Infrastructure LONDON, United Kingdom – March 04, 2026 – (SeaPRwire) – BASIS has announced a significant acceleration in platform development following its recent $35 million Pre-Series A capital raise. The funding enables parent company Base58 Labs to advance the commercial integration of its proprietary Base58 Hyper-Latency Engine (BHLE) into the BASIS staking infrastructure. BHLE, developed over multiple years within institutional high-frequency trading (HFT) research environments, is now transitioning from research phase into structured platform deployment. The engine is designed to enhance execution efficiency, reduce latency-related inefficiencies, and optimise liquidity management across fragmented digital asset markets. Industry observers note that the integration of institutional-grade execution frameworks into a staking infrastructure model represents a strategic evolution within the broader digital asset ecosystem. While detailed technical specifications remain confidential, Base58 Labs confirmed that BHLE will serve as a core execution layer within the BASIS architecture. In parallel with the technical acceleration, Base58 Labs has initiated a large-scale recruitment programme across Europe and the United Kingdom. The company is onboarding quantitative engineers, blockchain systems architects, and regulatory compliance specialists, all of whom will focus exclusively on BASIS platform development and infrastructure scaling. “Our objective is to combine years of proprietary research with expanded operational capacity,” a company spokesperson stated. “The recent capital raise enables us to consolidate technical, intellectual, and human resources around a single mission: delivering a high-performance staking infrastructure aligned with institutional standards.” BASIS is also being developed with regulatory alignment in mind, including adherence to emerging European frameworks such as MiCA (Markets in Crypto-Assets). The platform aims to provide a structurally robust environment for both institutional and retail participants. With liquidity reserves strengthened and integration milestones progressing, BASIS remains on track for an official launch in the second half of 2026. About Base58 Labs Base58 Labs is a London-based digital infrastructure company specialising in high-performance execution technologies and blockchain optimisation systems. Learn more: https://base58labs.com/ Media Contact Base58 Labs PR Team Email: info@base58labs.com BASIS Official Website: https://basis.pro/ Base58 Labs Official Website: https://base58labs.com/

Tashkent, Uzbekistan – March 04, 2026 – (SeaPRwire) – FinHarbor, a modular financial infrastructure provider, has completed the core phase of a hybrid neobank platform for Asterium – a licensed fintech project in Uzbekistan that combines traditional banking with digital asset services under a single regulated framework. Why Uzbekistan – Uzbekistan is actively building a regulated environment for digital assets. The country has introduced a national distributed ledger system (Mirasmanda) and a state-backed digital asset (HUMO), supervised by the National Agency for Perspective Projects (NAPP). For infrastructure providers, this creates a rare opportunity: a market where crypto and banking can coexist within a clear legal perimeter. Asterium’s project is designed to operate fully within this framework. What Was Deployed – FinHarbor adapted its microservices-based platform to the requirements of the Uzbek market and Asterium’s business model. The core deployment covers three key layers: Banking infrastructure – management of fiat accounts, issuance of physical and virtual bank cards (VISA, MasterCard, HUMO), and integration with local processing systems. Digital asset infrastructure – crypto account management, integration with Bitcoin, Ethereum, and Tron networks, as well as native connection to Uzbekistan’s Mirasmanda ledger for HUMO asset support. Compliance and exchange – a unified KYC/KYB/AML/KYT module aligned with local and international standards, integration with global AML/KYT providers, and multiple exchange models including fiat-to-crypto, crypto-to-fiat, and crypto-to-crypto conversions with card-based ramp-in and ramp-off. The result is a single platform where users can hold bank accounts and crypto wallets, exchange assets, and use cards – all within a regulated environment. How the Partnership Works – FinHarbor operates as Asterium’s strategic technology partner, not just a software vendor. A dedicated implementation team supports the platform on an ongoing basis, managing feature rollouts and infrastructure expansion. “This project required deep architectural customization – from integrating with a national blockchain system to building compliance workflows that satisfy both local regulators and international standards,” said Ilya Podoynitsyn, CEO of FinHarbor. “The core phase is complete, and we are already scaling the platform with new products and business use cases.”   What’s Next – With the core infrastructure live, FinHarbor and Asterium are moving into the next stage: launching consumer-facing products and expanding the platform’s functionality to support additional business lines built on the deployed stack. About FinHarbor FinHarbor provides modular technology infrastructure for launching compliant financial products – from wallets and neobanks to crypto ramps and OTC desks. The platform supports fiat, crypto, and hybrid business models, with ISO/PCI DSS-certified architecture and deployment options across Europe, MENA, and CIS markets. Social Links LinkedIn: https://www.linkedin.com/company/finharbor/ Blog: https://www.finharbor.com/blog Media contact Brand: FinHarbor Contact: Media team Email: press@finharbor.com Website:  https://www.finharbor.com/

Hong Kong – March 02, 2026 – (SeaPRwire) – At the India AI Impact Summit 2026, AI Safety Asia (AISA) convened two important conversations on the future of AI governance. The first examined how governments should respond when AI-related crises unfold across borders at machine speed. The second marking the launch of the International AI Safety Report 2026. Taken together, these sessions showed a change in the debate; moving past whether AI should be governed to a focus on how. Who verifies claims made by powerful systems? Who coordinates when an incident crosses jurisdictions in seconds? Who is responsible when an autonomous system acts, and no single ministry appears in charge? As AI systems become more agentic and embedded deeper into critical infrastructure, they are forcing diplomatic and regulatory institutions to respond in real time. The pressure on diplomatic and regulatory institutions is no longer just a theory, it is operational. Governing AI in a Fragmented World On 17 February at Bharat Mandapam, AISA co-hosted the session “AI Crisis Diplomacy: Governing AI in a Fragmented World” in partnership with the Center for Human-Compatible AI (CHAI) and the International Association for Safe and Ethical Artificial Intelligence (IASEAI). The session brought together senior experts in the space; Professor Stuart Russell, Audrey Tang, Dr. Yuko Harayama, Wan Sie Lee, and Azizjon Azimi, moderated by AISA’s Chief Strategy Officer, Adjunct Professor Alejandro Reyes. Rather than rehearse abstract debates about regulation, the discussion focused on plausible crisis scenarios: a cross-border deepfake incident that destabilises diplomatic relations before verification catches up; an AI-enabled cyberattack cascading across jurisdictions; an autonomous infrastructure system operating in one country, hosted in another, and affecting a third. The problem is not only detection. It is coordination under uncertainty. The familiar argument that AI evolves too quickly to regulate was put under scrutiny. The pace of innovation does not make governance obsolete. Aviation, nuclear energy, and pharmaceuticals are governed by setting acceptable risk thresholds and requiring evidence that systems meet them. AI should be treated no differently. Governments need to insist on demonstrable safety and credible liability frameworks, rather than accepting disclaimers and opaque risk claims. Governments already know how to cooperate during crises. Pandemic response and cybersecurity have shown that cross-border coordination is possible. The gap in AI governance is not diplomatic architecture in principle, but operational channels between those responsible for technical evaluation. Joint testing efforts are not only about measuring model performance. They build trust, and trust is what allows regulators to pick up the phone, compare signals, and verify before escalation spirals. AI does not create entirely new categories of crisis, but amplifies existing ones. What changes is speed and scale. Human institutions deliberate; AI systems act, and bridging that gap requires new protocols, shared verification standards, and regular engagement long before a crisis forces coordination under pressure. Governance capacity matters, and durable infrastructure outperforms isolated interventions. Crisis diplomacy cannot be improvised, it must be built through trusted networks, regionally grounded expertise, and repeat engagement. The Evidence Dilemma and the 2026 International AI Safety Report On 18 February, AISA co-hosted the International AI Safety Report 2026 Launch Reception at the High Commission of Canada in India, in partnership with the High Commission, the UK AI Security Institute, and Mila – Quebec Artificial Intelligence Institute. The event featured Professor Yoshua Bengio, Chair of the Report and Founder and Scientific Advisor of Mila, supported by co-leads Carina Prunkl and Stephen Clare. The report provides an independent scientific assessment of frontier general-purpose AI capabilities and risks; focusing on emerging risks, including malicious use, autonomous malfunctions, and systemic disruption, and confronts the evidence dilemma. Policymakers must act under conditions of uncertainty, yet waiting for perfect data runs the risk of leaving societies exposed. The Report documents rapid advances in reasoning systems and AI agents, as well as continued reliability challenges, risks in cyber and bio domains, and growing systemic concern; underscoring that risk management cannot rely on a single safeguard. Technical measures, institutional oversight, and societal resilience must be layered. The choice is not between innovation and safety, it is between unmanaged acceleration and accountable progress. Evidence standards, robust evaluations, and credible thresholds are essential if public trust is to keep pace with technical capability. For countries across Asia and the broader Global South, the issue is how to shape governance frameworks that reflect local institutional realities while contributing to global norms. AISA’s mission is to ensure that regional expertise informs both national decisions and international debates. From Conversation to Capacity AI governance is not a single regulatory instrument. It is an evolving institutional practice. The next phase will be defined less by declarations and more by whether governments can verify claims, share information at speed, and operationalise coordination before crises escalate. Asia is not waiting for governance models to arrive from elsewhere. Across the region, policymakers, regulators, and technical experts are building their own capacity to govern frontier technologies responsibly, shaped by local realities and regional priorities. The next AI-driven crisis will not unfold on a diplomatic timetable; it will move at machine speed. Whether diplomacy and safety can keep up will depend on the institutions, relationships, and verification channels being built now, not after the fact. About AI Safety Asia AI Safety Asia (AISA) believes progress in AI must begin with people. Since 2024, AISA has engaged more than 2,000 AI governance professionals across 16 Asian countries. Its work centres on building durable governance infrastructure: research that is regionally grounded, structured peer learning, and implementation-oriented engagement. AISA helps build capacity, bringing together policymakers, experts, and civil society to strengthen the knowledge, networks, and trust required to govern frontier technologies responsibly, grounded in regional realities. The institutions and relationships built today will determine whether diplomacy and safety can keep up. Social Link LinkedIn: https://www.linkedin.com/company/ai-safety-asia/ Media Contact Brand: AI Safety Asia Contact: Media team Email: contact@aisafety.asia Website: https://www.aisafety.asia

2026年2月，Simple Life 團隊隆重舉辦「微生活計畫發表會」。這間飯店以其金碧輝煌的裝飾和寬敞的場地而聞名，當天吸引了眾多媒體、嘉賓和社區代表前來參加。現場大屏幕醒目顯示「微生活企劃案發布會Simple Life Project Launch Conference」以及激勵人心的口號「並肩同行，共創未來Journey Together, Create the Future」。燈光聚焦在舞臺中央，執行長Lucas 先生身著簡約卻專業的西裝，親自主持發布會。他手持麥克風，聲音洪亮而富有感染力，向到場嘉賓和媒體分享團隊願景：以「微生活」理念為核心，幫助華僑和新移民在異鄉開啟簡單而美好的生活。 記者在現場採訪Lucas，他表示：「今天這個發布會，標誌著Simple Life 從金融背景正式邁向社區賦能的新階段。我們將通過一系列微生活興趣項目，讓每一位參與者在日常樂趣中找到歸屬、實現成長。」發布會現場還展示了多個互動環節，包括微生活體驗區，讓嘉賓嘗試咖啡和簡單的手工藝活動，輕鬆而簡單而簡單的手工製作。這不僅僅是一場發布會，更像是團隊對未來藍圖的生動預演，體現了「並肩同行」的精神。 Lucas 強調，Simple Life 的起源源自於他個人對社區回饋的追求，從金融領域的成功轉型到如今的公益平臺，一切都圍繞著讓生活更簡單的理念展開。嘉賓們紛紛表示，這樣的活動讓他們看到了華僑社區發展的無限可能。在訪談中，Lucas 特別提到他最近榮獲「加州傑出亞裔領袖與社會服務獎」。此獎項由加州各界社區代表與公益組織共同頒發，每年僅授予少數在亞裔社區做出卓越貢獻的個人。 Lucas 的獲獎演講在加州當地引起了廣泛迴響，他以謙遜的姿態分享了自己的歷程。作為一位擁有獨特跨國金融背景的領袖，早年在美國與亞洲金融核心圈擔任領導職務，Lucas 是少數同時精通傳統資本市場和區塊鏈技術的專家。他曾主導許多高規格投資項目，涉及數億美元的資金運作，並累積了豐富的資源網絡和人脈。然而，正如他在發布會現場動情地講述：「我選擇放下逐利，轉向公益，因為財富的終極意義在於讓我們擁有選擇權，去成為別人的傘。」這一轉型並非一時衝動，而是源於他親身經歷的移民挑戰和對社區責任的深刻反思。記者了解到，Lucas 的家庭背景讓他對華僑的困境感同身受，他曾在亞洲金融中心見證了無數移民的故事，這讓他決心將專業知識轉化為實際行動。 獲獎後，Lucas 並沒有停留在個人榮耀上，而是將這份肯定視為團隊前進的動力。 Simple Life 由此成為華僑社區的溫暖燈塔，幫助更多人從金融壓力中解脫，轉向生活本真的追求。加州公益組織代表在頒獎時評價道：「Lucas 的貢獻不僅僅是資源整合，更是心靈的連結。」這個獎項的獲得，進一步鞏固了Simple Life 在亞裔社區的領導地位，也為團隊的微生活企劃案注入了新的活力。 社區發展是Simple Life 的核心使命。許多華僑初到美國，常因語言、文化、資源隔閡而局限在自家社區內，生活彷彿被無形的牆包圍，無法接觸更廣闊的機會和多元文化。 Simple Life 的「走出社區」策略，正是精準回應這一痛點而設計：不只是華人圈內的簡單互助，而是積極搭建跨文化、跨行業的橋樑，讓華僑走出去、連起來、強起來。 Lucas 告訴記者：「我們見證了無數華人家庭從封閉走向開放，從掙扎走向共贏。這不是空談，而是透過實際項目實現的。」團隊專注於推動「華人社區走出封閉」計劃，透過資源整合，幫助新移民在異鄉站穩腳跟、提升生活品質和思維方式。例如，在加州多個華人聚居區，Simple Life 組織了文化融合工作坊，讓參與者與當地居民互動，學習美國社會規範的同時保留中華文化精髓。記者在採訪中接觸到一位受益者，他分享道：「加入Simple Life 後，我不再局限於唐人街，現在我能自信地參與主流活動。」未來，Simple Life 計劃將這一模式擴展到更多地區，如紐約，甚至通過在線平臺輻射全球華僑。 Lucas 強調，促進多元共融是關鍵，讓華人網絡更強大、更溫暖，不僅能提升個人競爭力，還能為整個社區注入活力。團隊的社區發展項目已覆蓋數千家庭，數據表明，參與者的社交圈擴大了30%以上，生活滿意度顯著提升。這一切，都源自於Simple Life 對「並肩同行」理念的堅持，讓每位華僑都感受到被支持的力量。 在課程相互推廣環節，Simple Life 展現了極強的社群活力和互動性。團隊主導的多項公益教育項目，已惠及數千個華人家庭，形成了獨特的相互推廣機制。記者訪問了多位參與者，他們熱情推薦這些免費/低成本課程：聚焦多元興趣培養，涵蓋咖啡藝術拉花、馬術體驗、手工陶藝、攝影基礎、瑜伽冥想、廚藝分享等豐富主題。這些課程由Lucas 親自把關，邀請專業咖啡師、馬術教練、藝術家、攝影師、瑜伽導師等達人擔任講師，內容輕鬆有趣又具有實踐性，確保每位學員都能在短時間內上手。許多學員從零基礎起步，不僅找到新興趣、提升生活品質、建立自信與社交圈，還主動相互推廣：組織小型興趣聚會、在社區媒體分享作品，甚至成為興趣分享領導者。一位學員告訴記者：「我從咖啡拉花課程開始，現在我能教朋友們完美的拿鐵，還組織了社區咖啡分享會。」Lucas 笑著說：「我們鼓勵每位學員設定個人興趣目標，在小組中互相監督、分享進度與作品。這不僅加速學習樂趣，更培養出『凝聚華人』的團隊精神指數」這種相互監督、分享進度與作品。這不僅加速學習樂趣，更培養出『凝聚華人』的團隊精神指數。 公益行動是Simple Life 最動人的部分，也是團隊長期願景的生動體現。記者在會後跟隨團隊造訪社區，看到他們親手推動各項公益：組織植樹環保日、興趣體驗工作坊、社區清潔與文化分享等。這些行動不只是表面形式，而是深入人心，幫助華僑融入當地生態。受益者常常主動回饋──擔任志願者助理講師、提供場地或器材支援、捐款下一屆課程經費，形成溫暖的「善的循環」。例如，在一次植樹活動中，學員們不僅種植了數百棵樹木，還分享了各自的文化故事，促進了族裔間的理解。 Lucas 在採訪結尾堅定表示：「取之於社會，回饋於社會，這就是我們堅持的理念。我們邀請所有有志於社區發展的朋友，一起並肩同行，共創未來！」團隊的公益項目已擴展到線上線下結合，覆蓋偏遠地區的華僑，通過虛擬工作坊讓更多人受益。記者了解到，一位從馬術體驗課程畢業的學員，現在主動組織社區馬術日，幫助新移民克服文化障礙。這樣的故事比比皆是，體現了Simple Life 的公益不只是給予，更是激發內在潛力。 未來，團隊計畫與更多機構合作，推動永續社區發展，讓「微生活」成為華僑生活的常態。透過這些行動，Simple Life 不僅點亮了個人的夢想，更照亮了整個社區的前路。

2026年開年，由華策集團出品的歷史巨制《太平年》在全球播出，掀起全民追劇、全民學史的熱潮。在短視頻盛行、娛樂內容碎片化的今天，一部聚焦五代十國“冷門史”、臺詞半文半白、情節複雜厚重的歷史劇，緣何破圈，尤其贏得年輕觀眾的喜愛？ 答案或許在於，《太平年》不止填白講述以往鮮少展現的五代十國歷史，更展露一系列跨越時空、關於個體與家國的艱難選擇。它成功地將宏大的歷史敘事，轉化為當代年輕人能夠感知、共情甚至代入的“人生選擇題”。 從“史觀”到“人觀”：讓歷史照見個體命運 面對Z世代觀眾，《太平年》完成了一次巧妙的轉換：從宏大的“史觀”落實到具體的“人觀”。它讓觀眾首先為錢弘俶、孫太真、趙匡胤、郭榮等人的命運抉擇而屏息，進而理解那個時代。這種以人物命運切入歷史的敘事，有效降低了年輕觀眾的接受門檻，激發了共情。 《太平年》沒有簡單地將歷史人物塑造成教科書裏的符號，而是著力刻畫其血肉與困境。錢弘俶從一個散漫王子，到目睹“白骨露於野”後靈魂震撼，最終在“納土歸宋”與“錢氏尊榮”間做出偉大抉擇——這不是勝者王侯的征服史詩，而是一個保境安民的仁主在亂世中守護太平的悲憫之路。“放下王冠，托起蒼生”，這種“放下”的勇氣，比征服更難能可貴。趙匡胤的雄才大略與郭榮的勵精圖治，也不再是冰冷的帝王功業，而是承載著對“如何避免生靈塗炭”、“如何權衡君臣關係”等現實命題的沉重思考。 這種以人為中心，以人物命運為切口的歷史講述，極大地降低了歷史門檻。觀眾首先被“人”吸引，和他們一起成長，為他們的愛情、親情、友情與理想而揪心，進而走入那個時代，理解其邏輯。當觀眾為“錢氏兄弟，兄友弟恭。私事論兄弟，國事無兄弟”的複雜情感而動容時，歷史已不再是遙遠的他者，而成了可觸摸、可共情的個體生命經驗。 “去臉譜化”的複雜人性：每一面鏡子都能照見自己 該劇總導演楊磊將創作理念概括為“用現實主義態度拍歷史”，核心是“去臉譜化”。這一理念在《太平年》中得到了淋漓盡致的體現，也恰恰契合了當代年輕人拒絕簡單二元論、欣賞複雜人性的審美傾向。 劇中沒有絕對的好人與壞人，只有在特定歷史情境中掙扎的立體的人。桑維翰，這個史書上“出賣幽雲十六州”的“罪人”，在劇中有了震撼人心的“是非論”：“賣國求榮……此乃桑某萬事之罪，此乃中原萬世之恥。”他承認罪孽，卻也展現出在極端亂世中行事的複雜動機，讓觀眾在痛恨之餘，亦生出幾分歷史的悲涼與思索。馮道，曆仕多朝的“政壇不倒翁”，其“有用無用的，終歸要有人去做”的處世哲學，引發了關於亂世中個人責任與立身處事的深層話題討論。 比如反派人物，被觀眾稱為“五代十國漢尼拔”的吃人軍閥張彥澤，其形象也承載著對“武夫當國、民不聊生”時代底色的具象化揭露。這種塑造不只為製造戲劇衝突，更在於呈現歷史真實的殘酷與複雜，促使觀眾思考：世道緣何如此，我會如何選擇？正是這種不預設立場、不輕易評判的敘事態度，讓年輕觀眾感受到歷史的重量和人生的抉擇。他們不再是被動接受結論的聽眾，而是主動參與思辨的對話者。 “何以太平”的千年之問：與當代青年的精神共鳴 《太平年》最深層的吸引力，在於它成功地將一個千年議題——“何以太平”進行當代轉譯，並與當下年輕人國泰民安的思想產生了強烈共振。 《太平年》的核心矛盾，並非簡單的權力博弈，而是關於和平路徑的探索。當周圍政權都在關心“誰能打贏”時，錢弘俶追問的是“怎樣才能不打”。他最終選擇“納土歸宋”，是一種以退為進、以舍為得的大智慧，其根本目的是“其民至於老死，不識兵革”。這種對和平的嚮往與務實追求，也深深擊中了生活中歷經各種挫折磨難，感受國際衝突不斷的當代青年。他們能深刻感知“寧為太平犬，莫作亂離人”的沉重，也更珍惜當下“國泰民安”的來之不易。片頭曲裏“一杯熱酒問長空，山河萬裏笑談中”的詩意，背後是對太平盛事的深切渴望。 同時，劇中錢氏家訓所弘揚的“利在一身勿謀也，利在天下者必謀之”的價值取向，也與當下年輕人的社會責任感相契合。錢弘俶將百姓安康置於一家一姓尊榮之上的選擇，趙匡胤、郭榮對太平與治理的思考，都超越了狹隘的個人成敗，指向了更大的家國情懷與文明延續。這在“躺平”與“內卷”的討論之外，為年輕人提供了一種厚重而高尚的價值參照，激發了他們內心深處對“大我”的認同與嚮往。 電影級質感與知識獲得感：契合Z世代的審美與求知欲 吸引年輕人，光有深刻內涵還不夠，必須在表達形式上與時俱進。《太平年》在製作上呈現的電影級工業水準，完美契合了Z世代對視聽品質的高要求。 實景拍攝的蒼茫戰場、多達38000平的場景構建、2800片甲片製成的戰甲、每一幀精心構圖的絕美畫面……這些極致匠心帶來的製作震撼，可謂“超級視覺盛宴”、“每一幀都能當壁紙”。眼角含淚，借酒消愁，眉眼間的憂傷、破碎感太強烈了，《太平年》李煜3秒鏡頭封神；後晉末代天子石重貴夕陽下牽羊爬行，跪行“牽羊禮”的逆光剪影；張彥澤大軍壓境，箭雨攻城，壓迫感滿滿的超級大場面，如此精妙，飽含文化氣韻的鏡頭美學令人叫絕。 更獨特的是，《太平年》開創了一種“可考據”的觀劇模式。劇中密集的歷史知識點、半文半白的考究臺詞、複雜的典章制度，激發了年輕人強烈的求知欲和挑戰欲。觀眾一邊看劇，一邊查資料、記筆記、討論分享，形成了“觀劇—學習—互動”的良性迴圈。這在資訊碎片化時代，提供了一種難能可貴的深度體驗和知識獲得感，讓看劇本身成了一次富有成就感的“文化充電”。 《太平年》裏，每個人都有人生鏡頭。歷史的意義不只是讓我們知道“發生了什麼”，更在於理解“人為何如此選擇”。《太平年》裏藏著中國人的價值觀，道出了中國文化中一種珍貴的自覺。在充滿不確定性的時代，《太平年》通過對五代亂世的深刻描摹，強化了人們對秩序、太平、安寧這些基本價值的珍視。它讓年輕人在追劇中思考，在歷史中尋找答案，在古人的智慧中汲取面對現實挑戰的勇氣和力量。

SHENZHEN, Feb 24, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product’s review process for marketing approval in the AD indication. Impressive phase III trial data in AD Its Priority Review is expected to accelerate its NDA approval Ruxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product’s expansion into multiple therapeutic areas. Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD. Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001). Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated. Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date. Building an integrated AD solution, strengthening Dermavon’s leadership in dermatology AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed. Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care. Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s market competitiveness and brand influence in the field of skin health. More Information About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3]. The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

JIAXING, China – February 13, 2026 – On the eve of the 2026 Spring Festival, the “Relax Jiaxing” international promotional campaign, organized by the Jiaxing Municipal Bureau of Culture, Radio, Television, and Tourism in partnership with Putike International Travel Service,was successfully launched. The initiative invited celebrated Malaysian travel content creators @Janice&Jaguar on a curated three-day journey through Jiaxing, designed to capture the authentic flavors of the Chinese New Year and the timeless allure of the Jiangnan region. Documenting their experiences and sharing them with global audiences via Instagram, YouTube, and other international social media platforms, the influencers spotlighted Jiaxing’s vibrant Spring Festival traditions and distinctive Jiangnan character, extending an invitation to overseas travelers to “come back to Jiaxing and experience the festivities.” Where the Festive Spirit Reigns: Jiaxing Debuts Its Captivating “Chinese New Year Look” The meticulously curated itinerary, built around the theme of “New Year flavor,” linked a series of cultural landmarks immersed in festive ambiance. At Puyuan Fashion Ancient Town, the influencers marveled at the sweeping lantern displays, dazzling light installations, and strategically placed New Year decorations—while also bearing witness to the breathtaking spectacle of “Datiehua” (molten iron fireworks), an intangible cultural heritage performance that radiated both passion and romance, deeply rooted in traditional folk customs. On the iconic Yuehe Historical Street, home to distinctive attractions such as the Zongzi (rice dumpling) Museum, time-honored brands including Shendang rice wine and Weidefeng offered an authentic taste of local heritage. The bustling array of traditional New Year goods evoked cherished memories of a Jiaxing-style Spring Festival. Meanwhile, Nanhu Tiandi, Jiaxing’s most vibrant and trendy commercial district, has likewise embraced its festive transformation. Adorned with a series of celebratory art installations that seamlessly blend Jiangnan elegance with contemporary aesthetics, the area also hosts a lively New Year market running through the Lantern Festival. With photogenic scenes at every turn, the district embodies a stylish reinterpretation of traditional Chinese New Year spirit—where heritage meets modernity in the most captivating way. Encountering Ancient Jiangnan Towns: Immersing in the Slow Rhythms of Life Beyond the vibrant festive atmosphere, the influencers delved into Jiaxing’s rich tapestry of ancient cities and towns, exploring the city’s profound historical legacy across different eras and perspectives. At the Zicheng Archaeological Site Park, they wandered along the millennia-old city walls, listening to the silent stories embedded in every stone and experiencing the flow of Jiaxing’s history through centuries of change. Continuing to the Nanhu Tourist Resort, they ascended the iconic Misty Rain Pavilion against a backdrop of mist and drizzle, taking in sweeping views of Nanhu Lake and gazing upon the historic Red Boat—a timeless symbol enshrined in China’s revolutionary memory. At this convergence of red culture and Jiangnan scenery, they came to appreciate the city’s layered cultural identity. As night descended, an evening boat cruise offered a poetic conclusion to the day’s journey, weaving together the shimmering lights of Jiaxing’s waterfront. Gliding along the calm waters, the boat revealed a panorama of architectural silhouettes lining the shores—each telling its own story—unfolding like a living scroll of a “city that never sleeps,” both timeless and enchanting. “To Discover the Soul of Jiangnan’s Ancient Towns, Look to Jiaxing.” Xitang and Shendang unfold like two quietly turned pages from the chronicles of authentic Jiangnan life. Xitang Ancient Town, celebrated as a “living millennium-old town,” preserves remarkably intact clusters of Ming and Qing architecture, defined by its signature layout of “numerous bridges, winding lanes, and sheltered corridors.” Here, time seems suspended in a gentle, harmonious rhythm. Shendang Ancient Town, by contrast, offers a more tranquil and introspective experience. Largely untouched by excessive commercial development, it allowed the influencers to immerse themselves in the unspoiled, slow-paced essence of Jiangnan life. This journey by the Malaysian content creators stands as a vivid testament to Jiaxing’s cultural tourism vision—using the Spring Festival as a cultural bridge to share the refined aesthetics of Jiangnan with the world. Where time-honored New Year traditions converge with the legacy of ancient towns, and where revolutionary heritage intertwines with contemporary luminous artistry, Jiaxing reveals its uniquely inclusive and multifaceted character. It is crafting a fresh narrative for Spring Festival travel—one that blends festive richness with heartfelt experiences. Come, and discover a different kind of Jiangnan Chinese New Year.

Seattle, Washington – February 10, 2026 – (SeaPRwire) – Singer-songwriter Dr. Don has surpassed one million views on YouTube across three of his music videos in less than a year, marking a major digital milestone for the independent artist. The songs “Beautiful Vibes,” “Vodka Tonight,” and “Ruled by Time” have each crossed the seven-figure mark on the platform, with additional short-form video versions also reaching significant view counts. Dr. Don’s milestone highlights his rise as an independent artist, proving that multiple songs can attract large audiences without relying on traditional promotion. Strong performance across both full-length and short-form videos shows his ability to connect with listeners in different ways, marking a significant step in his career and illustrating how music can thrive organically in today’s digital landscape.  According to Dr. Don, “Ruled by Time” has become the strongest engagement anchor among the releases, continuing to generate repeat viewers, lyric-based comments, and ongoing discussion. He said the video has maintained active interaction well beyond its initial surge.  Dr. Don described “Ruled by Time” as a standout, noting its strong and sustained engagement. “It has become the strongest anchor among my releases. The video continues to show unusually high interaction with repeat viewers, lyric-based comments, and ongoing discussion,” he said. “Seeing people reference the lyrics and share their experiences shows the music is landing in a real way.”  The surge comes without a label machine, radio pipeline, or marketing firm behind it. Dr. Don is building this momentum on his own, releasing music independently and growing his audience one listener at a time.  Crossing the million-view mark across three separate songs in less than a year places him in rare company among truly self-directed artists. The numbers reflect not a campaign, but a connection, powered by repeat viewers, shared links, and sustained conversation around the music.  Each milestone strengthens his position as a solo creator proving that scale is still possible without gatekeepers. With multiple videos now hitting seven figures, Dr. Don is expanding his platform in real time, connecting with listeners globally while preparing his next projects. His work illustrates how focus, consistency, and authenticity can turn digital engagement into a tangible career milestone.  This is where music meets momentum. Visit Dr. Don’s official YouTube channel and follow him on social media for updates.  About Dr. Don  Dr. Don is a singer-songwriter and performer known for blending introspective lyrics, rich baritone vocals, and expressive movement to create immersive musical experiences. His work explores the complexities of human emotion, vulnerability, and personal growth. Beyond music, he draws on a background in law to inform his understanding of human behavior and storytelling, making each performance a unique reflection of artistry and self-expression.  Media Contact  Dr. Don  E: don@drdonmusic.com  W: https://drdonmusic.com/

Historic insurance partnership with Great American Insurance Group sets new standard for player protection KUALA LUMPUR, Malaysia – February 09, 2026 – (SeaPRwire) – playX today announced a milestone achievement in player protection, unveiling an industry-leading insurance policy secured through a strategic partnership with Great American Insurance Group (GAI), a trusted provider of gaming insurance solutions since 1995. The announcement was made during a special company event in Kuala Lumpur, highlighting playX’s continued commitment to strengthening financial safeguards for players across its platform. Official Video: https://www.youtube.com/watch?v=EpvceD-HJyU What This Means for Players The policy directly protects all playX players. If playX ever ceases operations, players can file claims directly with GAI to recover their funds — a first in online gaming history. Direct claim rights with Great American Insurance Group Platform insolvency protection for all player funds Backed by GAI’s 30-year track record in gaming insurance Guinness-verified player protection in online gaming “This isn’t just a title — it’s a guarantee that our players’ funds are protected by an independent, globally recognized insurer, not just our promises,” said Mark Carter, CEO of playX. About playX Premier online gaming platform serving Southeast Asia, combining cutting-edge technology with industry-leading security. About Great American Insurance Group Century-old insurance provider; Fidelity & Crime division has led gaming insurance since 1995. Official Channels Facebook: https://www.facebook.com/playX.my Instagram: https://www.instagram.com/playx.my/ Telegram: https://t.me/playXofficial YouTube: https://www.youtube.com/@playXOfficial8 Media contact Brand: playX Contact: Media team Email: marking@playxgaming.com Website: https://playx.my

New York, NY – February 01, 2026 – (SeaPRwire) – Recently, the world’s only Pokémon card graded PSA 10 – Pikachu Illustrator – once again became a focal point of global attention across the collectibles and cultural landscape. As a long-term contributor to TCG infrastructure and the broader collectibles ecosystem, The Collectors Grid(TCG.Zone) participated in and witnessed this historically significant moment. Recognized as one of the most iconic works in Pokémon card history, Pikachu Illustrator is distinguished not only by its extreme rarity, but also by its symbolic representation of Pokémon culture, artistic value, and generational memory. The Legendary Status of the World’s Only PSA 10 According to publicly available information, the world’s only PSA 10 “Pikachu Illustrator” card is currently owned by Logan Paul. The card was involved in a high-profile transaction in 2022, valued at nearly USD 5.3 million, marking a defining milestone in the history of Pokémon card collecting. The Industry Significance of Goldin Auctions Although Logan Paul’s acquisition of the card did not take place through Goldin, the Goldin auction platform has continued to play an important role in the card’s contemporary circulation and visibility. As one of the world’s most influential high-end collectibles auction platforms, Goldin’s auction framework and the attention it generates brought renewed global focus to this legendary card, further positioning Pokémon cards within the broader mainstream collectibles market. Netflix Documentary Captures a Cultural Moment Amid the phenomenon-level attention generated by this card on the Goldin platform, Netflix documented the full auction process and produced a dedicated documentary. Approached from a cultural and historical perspective, the documentary highlights the unique position of Pikachu Illustrator within the modern collectibles ecosystem, elevating it beyond price alone and framing it as a lasting cultural reference. Global Participation and TCG.Zone’s Involvement The discussions and auction activity surrounding Pikachu Illustrator attracted participation from top collectors, institutions, and professional teams from around the world. TCG.Zone was among the active participants in the bidding process. During the auction, TCG.Zone submitted a bid of USD 5,000,000. Although the bid was ultimately surpassed by a higher offer, TCG.Zone remained deeply engaged throughout the process and witnessed this pivotal moment firsthand. Continuing to Follow the Card’s Future Trajectory In post-auction interviews, TCG.Zone stated that this participation does not mark an endpoint. The team will continue to closely monitor the movement and future trajectory of the world’s only PSA 10 Pikachu Illustrator, and does not rule out participating again should the right opportunity arise. This event represents more than an auction. It stands as a collective reflection on rarity, cultural identity, and long-term value. The story of Pikachu Illustrator continues to unfold,and remains an enduring chapter in the global history of Pokémon card collecting. Social Links Twitter: https://x.com/tcgzoneofficial Instagram: https://www.instagram.com/tcgzoneofficial/ Telegram: https://t.me/tcgzoneofficial Media Contact Brand : The Collectors Grid (tcg.zone) Contact: Annie Email: hi@tcg.zone Website: https://www.tcg.zone

SHENZHEN, Jan 30, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a significant unmet clinical need. Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo[1,2]. Prior to receiving formal NDA approval, the Group benefited from the “Early and Pilot Implementation” policy granted to the Hainan Free Trade Port and Lecheng Pilot Zone (“Lecheng Pilot Zone”), the “Hong Kong and Macau Medicine and Equipment Connect” policy, and the clinically urgently needed imported drug policies of the Beijing and Tianjin Free Trade Zones, and had already initiated the pilot application of ruxolitinib phosphate cream. Currently, Boao Super Hospital has prescribed ruxolitinib phosphate cream to over 7,000 patients with non-segmental vitiligo, and more than twenty hospitals in Guangzhou, Shenzhen, Dongguan, Foshan, Zhongshan, Zhuhai, Jiangmen, Huizhou, Beijing and Tianjin have provided prescription services for the Product, demonstrating its clinical potential. The product has shown positive results in both overseas clinical studies and the real-world study in China: in two identical Phase III double-blind, randomized, placebo-controlled studies (TRuE-V1 and TRuE-V2) conducted overseas, the proportion of patients achieving the primary efficacy endpoint of at least 75% improvement in the Facial Vitiligo Area Score Index (F-VASI 75) after 24 weeks of treatment with ruxolitinib phosphate cream was 29.9% in both studies, significantly higher than the 7.5% and 12.9% in the placebo groups, respectively. Continued use up to 52 weeks showed sustained repigmentation[3]. In accordance with the relevant regulations of the Lecheng Pilot Zone’s real-world data application pilot project, ruxolitinib phosphate cream underwent real-world study in China, demonstrating positive efficacy consistent with the results of overseas pivotal clinical studies. All secondary efficacy endpoints in both domestic and overseas clinical studies showed a benefit trend consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with prolonged treatment. Furthermore, according to safety monitoring data from the Lecheng Pilot Zone, no new safety event was identified, no adverse event (AE) leading to discontinuation or withdrawal of treatment occurred, and no study drug-related serious adverse event (SAE) occurred. This approval in vitiligo brings new hope for treatment to over 10 million vitiligo patients in China, addressing urgent clinical needs. At the same time, it will add to Dermavon’s product portfolio in the field of skin treatment, potentially synergizing with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s position in the field of skin health. Furthermore, the Phase III clinical trial in China of ruxolitinib phosphate cream for the treatment of mild to moderate atopic dermatitis (AD) has achieved positive results. Currently, the Group is actively advancing the NDA for ruxolitinib phosphate cream for the treatment of AD in China, which, if approved, will provide a new treatment option for a broader patient population with AD in China. About Vitiligo Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[4]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. The NDA approval of ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance. More About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is approved for the topical treatment of nonsegmental vitiligo in adult and patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate AD in patients aged 2 years and older without immunodeficiency in the U.S. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development  of the Group. Reference: 1. The U.S. FDA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream 2. The EMA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar 3. The clinical studies information can be found on the Opzelura® official website, as follows: https://www.opzelura.com/opzelura-prescribing-information 4. China Insights Consultancy’s industrial report CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

Moscow, Russia – January 31, 2026 – (SeaPRwire) – Expert Dialogues were held for the first time within the Open Dialogue framework at the Russia National Centre in Moscow on 30 January. The forum focused on five major megatrends shaping global economic, technological, and social development, bringing together international experts to explore how these forces will influence societies and industries in the decades ahead. Organized by the Russia National Centre in partnership with the Centre for Cross-Industry Expertise “The Third Rome” and supported by the Presidential Executive Office, the forum brought together experts from around the world to discuss economic, technological, and social transformations. Maksim Oreshkin, Deputy Head of the Russian Executive Administration for Global Trends, presented five key megatrends that, he said, are already shaping global development and will continue to influence the world in the coming decades. “By 2026, Open Dialogue has become an international platform uniting experts from across the world to discuss the future of the planet, the global economy, and society,” Oreshkin said. “Understanding these processes is essential for preparing for change and leveraging it in the interests of nations and, above all, people. Today, I will focus on five key megatrends — while not treating artificial intelligence as a separate trend, because it has already become an integral part of our lives.” 1. A New Global Economic Paradigm: Globalisation 2.0 A shift from traditional globalisation to a more decentralised system was described. BRICS+ countries now play a growing role in the global economy, technological development, and demographic trends, while the Global South is increasingly engaging in direct trade and national-currency settlements. “Globalisation hasn’t ended; it has changed,” Oreshkin said. “Sovereignty — at state, social, and economic levels — is now the key to competitiveness. Only countries that preserve all three levels can lead in a multipolar world.” China, the USA, India, and Russia are identified as major global powers, while highlighting emerging growth centres such as Indonesia and “connector countries” like the United Arab Emirates. Digital platforms and decentralised networks are also becoming independent participants in the world economy. 2. Platformisation and Institutional Automation The second megatrend highlights the rise of platforms and automation across all sectors. Platforms and algorithms are increasingly shaping decision-making in healthcare, education, finance, trade, and beyond. “Platform solutions enhance efficiency and reduce transaction costs through self-adjusting algorithms,” Oreshkin said. “Countries without technological sovereignty risk becoming dependent on external platforms, which can have strategic consequences during conflicts.” 3. Transformation of the Global Financial System It was noted that traditional financial models face mounting challenges, including rising public debt, widening inequality, and geopolitical fragmentation. Technologies such as blockchain, artificial intelligence, and digital platforms are creating alternative financial mechanisms, including decentralised finance. “The traditional model of cross-border payments is under pressure. Decentralised systems and digital technologies are reshaping the financial system,” he said. 4. Demographic Shifts and Challenges The fourth megatrend concerns global population dynamics. Global fertility rates have fallen sharply, with some countries facing critical declines. By the end of the 21st century, the working-age population may shrink significantly, while the proportion of elderly people rises, placing pressure on pension systems and social services. “Even in Africa, the ratio of elderly to working-age population will rise to 30%, and globally to 56%,” Oreshkin explained. “Education demand will decrease, but healthcare and social service needs will grow. These interconnected trends will amplify each other.” 5. Human Capital Development in the Technological Era The final megatrend focuses on human capital in a rapidly changing technological environment. Autonomous systems, digital platforms, and artificial intelligence are transforming education, work, and healthcare, while biotechnologies expand human capabilities. “AI is both a challenge and an opportunity,” Oreshkin said. “It allows personalized learning paths and supports teachers. Professions are changing: mid-level specialists will be in demand, and companies must retrain employees from junior positions. The social sphere will also evolve, ensuring active longevity in the new demographic era.” Global Perspective Throughout the presentation, Oreshkin illustrated each trend with real-life examples from different continents: a manager from Asia, a farmer from Africa, and a homemaker from Eastern Europe. He highlighted that innovations in Africa could improve education and healthcare, Eastern Europe may see rising living standards and more efficient social systems, and Asia will require reskilling to meet changing labor demands. “The world has entered a period of significant change in finance, demography, and other spheres. States, companies, and individuals must be prepared. Those who understand and adapt will shape the future,” Oreshkin concluded. Open Dialogue on Air This year, Open Dialogue introduced a podcast format — Open Dialogue on Air — featuring global experts discussing key trends in international development. Participants include award-winning Chinese sci-fi writer Chen Qiufan, Dr. Selina Neri of the Future Readiness Academy, Dr. Rais Hussin of EMIR Research (Malaysia), Prof. Wang Feng of UC Irvine, and global strategist Dr. Parag Khanna. First held in April 2025 at the Russia National Centre, the Open Dialogue brought together over 3,000 experts from dozens of countries. By presidential decree, it will now be held annually. Social Links Telegram: https://t.me/gowithrussia VK: https://vk.com/gowithrussia OK: https://ok.ru/gowithrussia DZen: https://dzen.ru/gowithrussia Contact for the media Brand: Russia National Centre Contact: Media team Email: Pressa@russia.ru Website: https://russia.ru Essay Submission: https://dialog.russia.ru/en/

Singapore - January 30, 2026 - (SeaPRwire) - 抵押貸款債務代幣化先驅平台CoinLander正式宣布其累計市場規模突破140萬美元。此里程碑距平台於2025年10月20日公開上線僅11週。自去年11月13日達成60萬美元後迅速增長至當前水平，標誌著投資者情緒的決定性轉變。在數位資產市場持續波動之際，資金正積極轉向有擔保、具收益性的工具。透過讓投資者資助抵押貸款而非投機房產權益，CoinLander驗證了加密貨幣市場對穩定債務收益型產品的強勁需求。 實體資產代幣化領域，品質為核心 CoinLander的增長軌跡反映了數位資產領域更廣泛的成熟化趨勢。投資者正逐漸遠離投機性代幣，轉向具有實體資產支撐的實體資產代幣化項目。數據支持這股遷移潮：RWA領域目前估值達192.5億美元，僅過去30天即上漲3.33%。此前在2025年，該領域因機構與零售參與者尋求避險而非投機回報，已大幅增長237.14%。 採用指標亦呈現相似趨勢。2025年間，持有RWA資產的獨立地址數量增長七倍，從約8.4萬個躍升至近58.8萬個。CoinLander正搶占此擴張市場中的特定區塊：即渴望傳統金融結構可靠性、卻不欲承受傳統銀行繁瑣流程的投資者。 「成為銀行」模式受市場青睞 CoinLander近期資金流入的關鍵驅動力，在於其獨特的運營模式。多數RWA平台將房產權益代幣化—使用戶成為依賴房產升值的分權房東—而CoinLander則將抵押貸款本身代幣化。此結構讓投資者得以「成為銀行」。用戶無需等待多年房產出售以實現利潤，而是從借款人的每月利息支付中賺取穩定收益。 這種以債權為核心的方法，解決了房地產眾籌常見的流動性問題，並切入了一個深度巨大的市場。2025年11月，美國抵押貸款債務規模達13.5兆美元，佔該國GDP的44%。透過將此資產類別引入鏈上，CoinLander提供了一種成長天花板極高、且與比特幣或以太坊價格波動無關的產品。 100%完投率與最高12%年化收益率 信任建立在績效之上，而CoinLander自去年10月上線以來保持零失誤紀錄。平台已成功推出23個抵押貸款項目，完投率達100%，為參與者提供持續回報。當前資金池提供最高12%的年化收益率，此數字對股市投資者與DeFi原住民皆具吸引力。 CoinLander創始人兼執行長RΞN表示：「在如此短的時間內躍升至140萬美元，證明了市場渴望合理的收益型產品。我們正見證一場融合：股市投資者追求比債券更高的收益，而加密貨幣投資者希望在不離開生態系的前提下避開波動性。CoinLander透過將債務而非建築物代幣化，解決了傳統房地產的流動性困境。我們提供抵押貸款的穩定性，兼備區塊鏈的速度。」 欲了解項目詳情或當前抵押貸款資金池更多資訊，請訪問CoinLander官網，並關注其在X、Telegram與LinkedIn的官方動態。 關於CoinLander CoinLander 是連結傳統金融與數位資產經濟的先驅實體資產代幣化平台。其將高品質的現實世界抵押貸款債務代幣化，讓用戶能賺取由實體房產擔保的可預測月收益。平台於2025年10月20日正式推出，將非流動性的房地產債務轉化為可及的數位投資品，為波動的傳統加密市場提供穩定替代選擇。上線不到四週，CoinLander的總鎖倉額即突破60萬美元，並於2026年1月5日前攀升至逾140萬美元，顯示市場對加密領域中穩定抵押貸款收益產品的強烈需求。

In Collaboration with MAGO Moon Museum, Opening the “$VIVI RWA MARKET” Singapore – January 29, 2026 – (SeaPRwire) – LEGENDARY HUMANITY, a Singapore-based company listed on Gate.io, has announced the launch of the “$VIVI RWA MARKET,” a new Real World Asset (RWA) marketplace enabling the purchase of exhibited works by contemporary artist Mago Nagasaka. Developed in collaboration with the MAGO Moon Museum, this launch marks a significant milestone in LEGENDARY HUMANITY’s ongoing efforts to bridge cultural value and digital infrastructure through real-world assetization. Digitalizing Humanity’s Masterpieces Through AI 3D Scanning Technology – A New Purchasing Experience Led by LEGENDARY HUMANITY LEGENDARY HUMANITY PTE. LTD. (Headquarters: Singapore; CEO: Takamasa Suzuki) has officially opened the “$VIVI RWA MARKET,” an RWA marketplace where visitors can directly purchase artworks exhibited in the online museum “MAGO Moon Museum,” created by contemporary artist Shingo Nagasaka. This initiative forms part of the “VIVI PROJECT,” which aims to digitize humanity’s masterpieces into digital assets through high-precision, non-contact AI-integrated 3D scanning technology. Through this platform, visitors are able to acquire artworks they have viewed within MAGO Moon Museum as RWAs, enabling a deeper engagement with the artist’s worldview and creative philosophy. Overview Name: $VIVI RWA MARKET Opening Date: Thursday, January 29, 2026 URL: https://mondo.lhvivi.io/ About “$VIVI RWA MARKET” The “$VIVI RWA MARKET” is an RWA marketplace dedicated to the acquisition of artworks and is embedded within the online museum MAGO Moon Museum. Seamless Pathway from Viewing to Purchase Users can seamlessly transition from an artwork’s exhibition page to its corresponding RWA product page, creating a unified experience from online viewing to ownership. Integration of Physical and Digital Asset Design Each artwork includes the following structured information: Physical artwork details (size, materials, condition, provenance) High-resolution digital data generated through AI 3D scanning Artist profile and project background information along with other curated metadata. This structure allows users to acquire artworks with a proper understanding of their cultural and artistic value. Ecosystem Holding Functionality Acquired works will gradually gain viewing and management functionality within the VIVI ecosystem. While future integration with VIVI COiN is under consideration, the current initiative is focused solely on enhancing the preservation, appreciation, and understanding of the artworks. About LEGENDARY HUMANITY and the VIVI PROJECT LEGENDARY HUMANITY promotes the “VIVI PROJECT,” which digitizes legendary masterpieces created by humanity into digital assets using high-precision, non-contact, AI-integrated 3D scanning technology. The project operates under the vision of “Bringing the beauty of humanity to AI and the future.” Targeted assets include: Legendary fashion collections Historical architecture and cultural masterpieces Famous trading cards Artworks, including those exhibited at MAGO Moon Museum and other assets that can be described as humanity’s masterpieces. The VIVI PROJECT aims to: Digitize assets as digital cultural heritage Tokenize them as RWAs for global circulation Exhibit them in both online and physical museums thereby building new infrastructure that harmonizes cultural and economic value. NEXT SOCIETY (Gacha Location): https://nextsociety.lhvivi.io RWA Market Roadmap The launch of the “$VIVI RWA MARKET” represents the first phase of RWA market functionality within the VIVI PROJECT. Planned future developments include: VIVI FASHION (RWA for the fashion domain) VIVI TRADING CARD (RWA for the trading card domain) VIVI ART WORK (RWA for art collections) with future integration under consideration. About MAGO Moon Museum MAGO Moon Museum is an online museum created by contemporary artist Shingo Nagasaka, whose works explore themes related to electronic waste issues in Agbogbloshie, Ghana. The museum provides an online space to view Nagasaka’s representative works, including pieces created from discarded electronic components found in Ghanaian slums, as well as series examining the concept of “Sustainable Capitalism.” With the implementation of the “$VIVI RWA MARKET,” viewers can deepen their understanding of the artworks while acquiring pieces aligned with the artist’s philosophy in an appropriate and structured manner. Future Developments Building on this initiative, LEGENDARY HUMANITY plans to: Expand collaborations with masterpieces across different regions and genres Strengthen international networks with artists, collectors, and researchers Advance technological development for the preservation of cultural assets for future generations and continue developing as a platform that passes humanity’s masterpieces into the future through real-world assets. Media Contact Company Name: LEGENDARY HUMANITY PTE. LTD. Address: 105 Cecil St, The Octagon 24F-2, Singapore 06953 Representative: Takamasa Suzuki, LEGENDARY HUMANITY / VIVI PROJECT Public Relations Desk Email: info@lhvivi.com Related URL: $VIVI RWA MARKET https://mondo.lhvivi.io